Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade

Gastric cancer overexpressing the human epidermal growth factor 2 (HER2) protein has a poor outcome, although a combination of chemotherapy and the anti-HER2 antibody trastuzumab has been approved for the treatment of advanced gastric cancer. Vascular endothelial growth factor (VEGF) expression in g...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Rohit, Kim, Woo Jin, Kim, Pyeung-Hyeun, Hong, Hyo Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849567/
https://www.ncbi.nlm.nih.gov/pubmed/24176949
http://dx.doi.org/10.1038/emm.2013.111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849567/
https://www.ncbi.nlm.nih.gov/pubmed/24176949
http://dx.doi.org/10.1038/emm.2013.111

Ejemplares similares